Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2009

Open Access 01-12-2009 | Research

Radical cyberknife radiosurgery with tumor tracking: an effective treatment for inoperable small peripheral stage I non-small cell lung cancer

Authors: Brian T Collins, Saloomeh Vahdat, Kelly Erickson, Sean P Collins, Simeng Suy, Xia Yu, Ying Zhang, Deepa Subramaniam, Cristina A Reichner, Ismet Sarikaya, Giuseppe Esposito, Shadi Yousefi, Carlos Jamis-Dow, Filip Banovac, Eric D Anderson

Published in: Journal of Hematology & Oncology | Issue 1/2009

Login to get access

Abstract

Objective

Curative surgery is not an option for many patients with clinical stage I non-small-cell lung carcinoma (NSCLC), but radical radiosurgery may be effective.

Methods

Inoperable patients with small peripheral clinical stage I NSCLC were enrolled in this study. Three-to-five fiducial markers were implanted in or near tumors under CT guidance. Gross tumor volumes (GTVs) were contoured using lung windows. The GTV margin was expanded by 5 mm to establish the planning treatment volume (PTV). A dose of 42–60 Gy was delivered to the PTV in 3 equal fractions in less than 2 weeks using the CyberKnife radiosurgery system. The 30-Gy isodose contour extended at least 1 cm from the GTV. Physical examination, CT imaging and pulmonary function testing were completed at 6 months intervals for three years following treatment.

Results

Twenty patients with an average maximum tumor diameter of 2.2 cm (range, 1.1 – 3.5 cm) and a mean FEV1 of 1.08 liters (range, 0.53 – 1.71 L) were treated. Pneumothorax requiring tube thoracostomy occurred following CT-guided fiducial placement in 25% of the patients. All patients completed treatment with few acute side effects and no procedure-related mortality. Transient chest wall discomfort developed in 8 of the 12 patients with lesions within 5 mm of the pleura. The mean percentage of the total lung volume receiving a minimum of 15 Gy was 7.3% (range, 2.4% to 11.3%). One patient who received concurrent gefitinib developed short-lived, grade III radiation pneumonitis. The mean percent predicted DLCO decreased by 9% and 11% at 6 and 12 months, respectively. There were no local failures, regional lymph node recurrences or distant metastases. With a median follow-up of 25 months for the surviving patients, Kaplan-Meier overall survival estimate at 2 years was 87%, with deaths due to COPD progression.

Conclusion

Radical CyberKnife radiosurgery is a well-tolerated treatment option for inoperable patients with small, peripheral stage I NSCLC. Effective doses and adequate margins are likely to have contributed to the optimal early local control seen in this study.
Appendix
Available only for authorised users
Literature
1.
Ginsberg RJ, Rubinstein LV: Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995, 60: 615-622. 10.1016/0003-4975(95)00537-U. discussion 622–613CrossRefPubMed
2.
Swanson SJ, Herndon JE, D'Amico TA, Demmy TL, McKenna RJ, Green MR, Sugarbaker DJ: Video-assisted thoracic surgery lobectomy: report of CALGB 39802 – a prospective, multi-institution feasibility study. J Clin Oncol. 2007, 25: 4993-4997. 10.1200/JCO.2007.12.6649.CrossRefPubMed
3.
Allen MS, Darling GE, Pechet TT, Mitchell JD, Herndon JE, Landreneau RJ, Inculet RI, Jones DR, Meyers BF, Harpole DH, Putnam JB, Rusch VW: Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg. 2006, 81: 1013-1019. 10.1016/j.athoracsur.2005.06.066. discussion 1019–1020CrossRefPubMed
4.
Handy JR, Asaph JW, Skokan L, Reed CE, Koh S, Brooks G, Douville EC, Tsen AC, Ott GY, Silvestri GA: What happens to patients undergoing lung cancer surgery? Outcomes and quality of life before and after surgery. Chest. 2002, 122: 21-30. 10.1378/chest.122.1.21.CrossRefPubMed
5.
El-Sherif A, Gooding WE, Santos R, Pettiford B, Ferson PF, Fernando HC, Urda SJ, Luketich JD, Landreneau RJ: Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis. Ann Thorac Surg. 2006, 82: 408-415. 10.1016/j.athoracsur.2006.02.029. discussion 415–406CrossRefPubMed
6.
Qiao X, Tullgren O, Lax I, Sirzen F, Lewensohn R: The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer. 2003, 41: 1-11. 10.1016/S0169-5002(03)00152-1.CrossRefPubMed
7.
Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Palmar M: Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol. 1999, 52: 137-148. 10.1016/S0167-8140(99)00087-0.CrossRefPubMed
8.
Withers HR, Taylor JM, Maciejewski B: The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988, 27: 131-146. 10.3109/02841868809090333.CrossRefPubMed
9.
Lax I, Panettieri V, Wennberg B, Amor Duch M, Naslund I, Baumann P, Gagliardi G: Dose distributions in SBRT of lung tumors: Comparison between two different treatment planning algorithms and Monte-Carlo simulation including breathing motions. Acta Oncol. 2006, 45: 978-988. 10.1080/02841860600900050.CrossRefPubMed
10.
McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD: Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005, 63: 1010-1015.CrossRefPubMed
11.
Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M, Fletcher J: Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006, 24: 4833-4839. 10.1200/JCO.2006.07.5937.CrossRefPubMed
12.
Timmerman R, Papiez L, McGarry R, Likes L, DesRosiers C, Frost S, Williams M: Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest. 2003, 124: 1946-1955. 10.1378/chest.124.5.1946.CrossRefPubMed
13.
Timmerman RD, Park C, Kavanagh BD: The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J Thorac Oncol. 2007, 2: S101-112. 10.1097/JTO.0b013e318074e4fa.CrossRefPubMed
14.
Collins BT, Erickson K, Reichner CA, Collins SP, Gagnon GJ, Dieterich S, McRae DA, Zhang Y, Yousefi S, Levy E, Chang T, Jamis-Dow C, Banovac F, Anderson ED: Radical stereotactic radiosurgery with real-time tumor motion tracking in the treatment of small peripheral lung tumors. Radiat Oncol. 2007, 2: 39-10.1186/1748-717X-2-39.PubMedCentralCrossRefPubMed
15.
Wong KH, Dieterich S, Tang J, Cleary K: Quantitative measurement of CyberKnife robotic arm steering. Technol Cancer Res Treat. 2007, 6: 589-594.CrossRefPubMed
16.
Giraud P, Antoine M, Larrouy A, Milleron B, Callard P, De Rycke Y, Carette MF, Rosenwald JC, Cosset JM, Housset M, Touboul E: Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys. 2000, 48: 1015-1024. 10.1016/S0360-3016(00)00750-1.CrossRefPubMed
17.
Goldstein NS, Ferkowicz M, Kestin L, Chmielewski GW, Welsh RJ: Wedge resection margin distances and residual adenocarcinoma in lobectomy specimens. Am J Clin Pathol. 2003, 120: 720-724. 10.1309/P47FYW5U4CRQ0WFE.CrossRefPubMed
18.
Colice GL, Shafazand S, Griffin JP, Keenan R, Bolliger CT: Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines. Chest. 2007, 132: 161S-177S. 10.1378/chest.07-1359. 2CrossRefPubMed
19.
Banovac F, McRae D, Dieterich S, Wong K, Dias L, Chang T: Percutaneous Placement of Fiducial Markers for Thoracic Malignancies. Robotic Radiosurgery: Treating Tumors that Move with Respiration. Edited by: Urschel HC, Kresel JJ, Luketich JD, et al. 2007, Berlin: Springer-Verlag, 15-29.
20.
Yousefi S, Collins BT, Reichner CA, Anderson ED, Jamis-Dow C, Gagnon G, Malik S, Marshall B, Chang T, Banovac F: Complications of thoracic computed tomography-guided fiducial placement for the purpose of stereotactic body radiation therapy. Clin Lung Cancer. 2007, 8: 252-256. 10.3816/CLC.2007.n.002.CrossRefPubMed
21.
Program, CTE: Common Terminology Criteria for Adverse Events, Version 3.0. 2006, DCTD N, NIH, DHHS
22.
Wisnivesky JP, Yankelevitz D, Henschke CI: The effect of tumor size on curability of stage I non-small cell lung cancers. Chest. 2004, 126: 761-765. 10.1378/chest.126.3.761.CrossRefPubMed
23.
Ketchedjian A, Daly BD, Fernando HC, Florin L, Hunter CJ, Morelli DM, Shemin RJ: Location as an important predictor of lymph node involvement for pulmonary adenocarcinoma. J Thorac Cardiovasc Surg. 2006, 132: 544-548. 10.1016/j.jtcvs.2006.05.023.CrossRefPubMed
24.
Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, Yamashita T, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Hirokawa Y, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K: Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004, 101: 1623-1631. 10.1002/cncr.20539.CrossRefPubMed
25.
Barton M: Tables of equivalent dose in 2 Gy fractions: a simple application of the linear quadratic formula. Int J Radiat Oncol Biol Phys. 1995, 31: 371-378.CrossRefPubMed
26.
Group LCS: Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med. 1986, 315: 1377-1381.CrossRef
27.
Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ, Perry MC, Livingston RB, Johnson DH: A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med. 2000, 343: 1217-1222. 10.1056/NEJM200010263431703.CrossRefPubMed
28.
Papiez L, Timmerman R, DesRosiers C, Randall M: Extracranial stereotactic radioablation: physical principles. Acta Oncol. 2003, 42: 882-894. 10.1080/02841860310013490.CrossRefPubMed
29.
Aoki T, Nagata Y, Negoro Y, Takayama K, Mizowaki T, Kokubo M, Oya N, Mitsumori M, Hiraoka M: Evaluation of lung injury after three-dimensional conformal stereotactic radiation therapy for solitary lung tumors: CT appearance. Radiology. 2004, 230: 101-108. 10.1148/radiol.2301021226.CrossRefPubMed
30.
Kimura T, Matsuura K, Murakami Y, Hashimoto Y, Kenjo M, Kaneyasu Y, Wadasaki K, Hirokawa Y, Ito K, Okawa M: CT appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: are patients with pulmonary emphysema also candidates for SBRT for lung cancers?. Int J Radiat Oncol Biol Phys. 2006, 66: 483-491.CrossRefPubMed
31.
Takeda A, Kunieda E, Takeda T, Tanaka M, Sanuki N, Fujii H, Shigematsu N, Kubo A: Possible Misinterpretation of Demarcated Solid Patterns of Radiation Fibrosis on CT Scans as Tumor Recurrence in Patients Receiving Hypofractionated Stereotactic Radiotherapy for Lung Cancer. Int J Radiat Oncol Biol Phys. 2008, 70: 1057-1065.CrossRefPubMed
32.
Takeda T, Takeda A, Kunieda E, Ishizaka A, Takemasa K, Shimada K, Yamamoto S, Shigematsu N, Kawaguchi O, Fukada J, Ohashi T, Kuribayashi S, Kubo A: Radiation injury after hypofractionated stereotactic radiotherapy for peripheral small lung tumors: serial changes on CT. AJR Am J Roentgenol. 2004, 182: 1123-1128.CrossRefPubMed
33.
Hoopes DJ, Tann M, Fletcher JW, Forquer JA, Lin PF, Lo SS, Timmerman RD, McGarry RC: FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer. 2007, 56: 229-234. 10.1016/j.lungcan.2006.12.009.CrossRefPubMed
34.
Ballonoff A, Kavanagh B, Schefter T: The effect of novel molecularly targetted agents on normal lung after SBRT to pulmonary maignancies. 8th International Stereotactic Radiosurgery Society Congress. San Francisco, CA. 2007
35.
Wang JS, Abboud RT, Wang LM: Effect of lung resection on exercise capacity and on carbon monoxide diffusing capacity during exercise. Chest. 2006, 129: 863-872. 10.1378/chest.129.4.863.CrossRefPubMed
36.
Le QT, Loo BW, Ho A, Cotrutz C, Koong AC, Wakelee H, Kee ST, Constantinescu D, Whyte RI, Donington J: Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. Journal of Thoracic Oncology. 2006, 1: 802-809. 10.1097/01243894-200610000-00008.CrossRefPubMed
37.
Pennathur A, Luketich JD, Burton S, Abbas G, Heron DE, Fernando HC, Gooding WE, Ozhasoglu C, Ireland J, Landreneau RJ, Christie NA: Stereotactic radiosurgery for the treatment of lung neoplasm: initial experience. Ann Thorac Surg. 2007, 83: 1820-1824. 10.1016/j.athoracsur.2006.11.077. discussion 1824–1825CrossRefPubMed
38.
Brown WT, Wu X, Amendola B, Perman M, Han H, Fayad F, Garcia S, Lewin A, Abitbol A, de la Zerda A, Schwade JG: Treatment of early non-small cell lung cancer, stage IA, by image-guided robotic stereotactic radioablation – CyberKnife. Cancer J. 2007, 13: 87-94. 10.1097/PPO.0b013e31803c5415.CrossRefPubMed
39.
Nyman J, Johansson KA, Hulten U: Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer – mature results for medically inoperable patients. Lung Cancer. 2006, 51: 97-103. 10.1016/j.lungcan.2005.08.011.CrossRefPubMed
40.
Anantham D, Feller-Kopman D, Shanmugham LN, Berman SM, DeCamp MM, Gangadharan SP, Eberhardt R, Herth F, Ernst A: Electromagnetic navigation bronchoscopy-guided fiducial placement for robotic stereotactic radiosurgery of lung tumors: a feasibility study. Chest. 2007, 132: 930-935. 10.1378/chest.07-0522.CrossRefPubMed
41.
Fu D, Kahn R, Wang B, Wang H, Mu Z, Park J, Kuduvalli G, Maurer CR: Xsight Lung Tracking System: A Fiducial-less Method for Respiratory Motion Tracking. Robotic Radiosurgery: Treating Tumors that Move with Respiration. Edited by: Urschel HC, Kresl JJ, Luketich JD, et al. 2007, Berlin: Springer-Verlag, 15-29.
42.
Reichner CA, Collins BT, Gagnon GJ, Malik S, Jamis-Dow C, Anderson ED: The placement of gold fiducials for CyberKnife stereotactic radiosurgery using a modified transbronchial needle aspiration technique. Journal of Bronchology. 2005, 12: 193-195. 10.1097/01.lab.0000186345.85025.41.CrossRef
Metadata
Title
Radical cyberknife radiosurgery with tumor tracking: an effective treatment for inoperable small peripheral stage I non-small cell lung cancer
Authors
Brian T Collins
Saloomeh Vahdat
Kelly Erickson
Sean P Collins
Simeng Suy
Xia Yu
Ying Zhang
Deepa Subramaniam
Cristina A Reichner
Ismet Sarikaya
Giuseppe Esposito
Shadi Yousefi
Carlos Jamis-Dow
Filip Banovac
Eric D Anderson
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2009
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-2-1

Other articles of this Issue 1/2009

Journal of Hematology & Oncology 1/2009 Go to the issue

Review

Vorinostat in solid and hematologic malignancies

Research

SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status

Research

Skeletal Plasmacytoma: Progression of disease and impact of local treatment; an analysis of SEER database

Letter to the Editor

Multiple Myeloma Involving Skin and Pulmonary Parenchyma after Autologous Stem Cell Transplantation

Review

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib

Research

Different altered stage correlative expression of high abundance acute-phase proteins in sera of patients with epithelial ovarian carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits